Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

45% Stake in Shanghai Schering-Plough JV For Sale

publication date: May 23, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Two China-based minority owners of the joint venture known as Shanghai Schering-Plough Industry Corp. Ltd. have announced their intentions to sell their participation in the entity. The majority owner, the giant pharma Schering-Plough (NYSE: SGP), will retain its 55% interest in the JV, and the big pharma will also have right of first refusal on buying the 45% minority stake. The asking price for the 45% piece of Shanghai Schering-Plough is 66.3 million RMB ($9.6 million).  More details...

Stock Symbol: (NYSE: SGP)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors